黑料吃瓜群网

Duchenne muscular dystrophy (DMD), the most common fatal genetic disease in children,聽may soon have a cure聽thanks to groundbreaking US research.

Scientists used CRISPR gene editing to halt DMD聽in dogs, which, as聽a large mammal, suggests that聽a lifesaving treatment for children should follow soon.

The research was conducted聽by the , and documents show significant improvement in the muscle fibres of dogs with DMD.

Researchers used a single-cut gene-editing technique to restore dystrophin in muscle and heart tissue by up to 92% of normal levels. Scientists have estimated a 15% threshold is needed to significantly help patients.

DMD聽is聽caused by a mutation that inhibits the production of dystrophin, a protein critical for muscle function.The disease,聽which affects one in 5000 boys, leads to muscle and heart failure聽and premature death by the early 30s. Patients are forced into wheelchairs as their muscles degenerate and eventually onto respirators as their diaphragms weaken. No effective treatment exists, though scientists have known for decades that a defect in the聽dystrophingene causes the condition.

鈥淐hildren with DMD often die either because their heart loses the strength to pump or their diaphragm becomes too weak to breathe,鈥� said聽Dr聽Eric Olson, Director of UT聽Southwestern鈥檚聽Hamon Center for Regenerative Science and Medicine. 鈥淭his encouraging level of dystrophin expression would hopefully prevent that from happening.鈥�

Proof of concept

The study, published in聽 journal, establishes the proof of concept for single-cut gene editing in dystrophic muscle and represents a major step towards a clinical trial. Already Dr聽Olson鈥檚 team has corrected DMD mutations in聽mice聽and聽human cells聽by making single cuts at strategic points of the mutated DNA.

The latest research applied the same technique in four dogs that shared the type of mutation most commonly seen in DMD patients. Scientists used a harmless virus called adeno-associated virus (AAV) to deliver CRISPR gene-editing components to exon 51, one of the 79 exons that comprise the聽dystrophin聽gene.

CRISPR edited the exon, and within several weeks the missing protein was restored in muscle tissue throughout the body, including 92% correction in the heart and 58% in the diaphragm, the main muscle needed for breathing.

鈥淥ur strategy is different from other therapeutic approaches for DMD because it edits the mutation that causes the disease and restores normal expression of the repaired dystrophin,鈥� said聽Dr聽Leonela Amoasii, lead author of the study. 鈥淏ut we have more to do before we can use this clinically.鈥�

Dr Leonela Amoasii works in the Olson lab at UT聽Southwestern Medical Center.聽Image credit: 漏UT聽Southwestern

The lab will next conduct longer-term studies to measure whether the dystrophin levels remain stable and to ensure the gene edits do not have adverse side effects.

Dr聽Olson hopes the next step beyond dogs is a clinical trial, which would be among several that UT聽Southwestern鈥檚 gene therapy centre aims to launch in the coming years to address聽numerous deadly childhood diseases.

Top image credit: 漏stock.adobe.com/au/ChiccoDodiFC